DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes

Information source: Takeda
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension; Diabetes

Intervention: Placebo (Drug); Azilsartan medoxomil (Drug); Azilsartan medoxomil (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Takeda

Official(s) and/or principal investigator(s):
Director, Clinical Science, Study Director, Affiliation: Takeda

Summary

The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus (T2DM) participants whose glycemic control was inadequate on metformin alone.

Clinical Details

Official title: A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects With Hypertension and Type 2 Diabetes

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure

Secondary outcome:

Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure

Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

Percentage of Participants Requiring Rescue Glycemic Therapy

Time to First Glycemic Rescue

Change From Baseline in HbA1c

Change From Baseline in Fasting Plasma Glucose

Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)

Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT

Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT

Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT

Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT

Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT

Detailed description: The study included a Screening Period of up to 4 weeks, which coincided with a 2-week single-blind, placebo Run-in Period, a 24 week Treatment Period, and a 2-week Follow-up Period. The duration of the study was approximately 30 weeks. The planned number of participants (n=450) was not reached; actual enrollment consisted of 105 particpants. Due to low enrollment this study was terminated early by Takeda.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Was male or female and ≥18 years. 2. Had type 2 diabetes mellitus with HbA1c of ≥7. 5 to ≤9. 5% at Screening. 3. Was treated with metformin alone (no treatment with any antidiabetic agents other than metformin within the 3 months prior to Screening) and was experiencing inadequate glycemic control. The participant should have received metformin monotherapy for ≥8 weeks prior to Screening at a stable dose ≥1500 mg). Participants with a maximum tolerated dose (MTD) that was documented to be less than 1500 mg of metformin could also be enrolled if this dose had been stable for 8 weeks prior to Screening. 4. Was treated with antihypertensive therapy and had a mean, trough, sitting clinic

systolic blood pressure (SBP) ≥135 and < 160 mm Hg on Day - 1 (after washout of prior

antihypertensive therapy) or the participant had not received antihypertensive treatment within 28 days before Screening and had a mean sitting clinic SBP ≥135 and

< 160 mm Hg at the Screening Visit and on Day - 1.

5. Had clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or results that were deemed not clinically significant in this participant population for inclusion in this study, by the investigator. Exclusion Criteria: 1. Had a mean, trough, sitting clinic diastolic blood pressure (DBP) ≥ 100 mm Hg at Day

- 1.

2. Had type 1 or poorly controlled type 2 diabetes mellitus (HbA1c >9. 5%) at Screening. 3. Was taking or expected to take an excluded medication. 4. Had a history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attack. 5. Had clinically significant cardiac conduction defects (for example, 3rd degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation). 6. Had hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease. 7. Had secondary hypertension of any etiology (e. g., renovascular disease, pheochromocytoma, Cushing's syndrome). 8. Had renal dysfunction defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1. 73 m2 at Screening. 9. Had albuminuria defined as >200 mg/g at Screening. 10. Had known or suspected unilateral or bilateral renal artery stenosis. 11. Had unexplained microhematuria ≥3 RBCs/HPF or macrohematuria at Screening and confirmed on repeat testing. 12. Treatment with antidiabetic agents (sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides, thiazolidinediones (TZDs), and/or insulin) other than metformin during the 3 months prior to Screening. 13. Had hyperkalemia as defined by central laboratory normal reference range at Screening.

Locations and Contacts

Birmingham, Alabama, United States

Green Valley, Arizona, United States

Tempe, Arizona, United States

Tucson, Arizona, United States

Buena Park, California, United States

Hawaiian Gardens, California, United States

Norwalk, California, United States

Paramount, California, United States

Rancho Cucamonga, California, United States

Sacramento, California, United States

San Diego, California, United States

Tustin, California, United States

Denver, Colorado, United States

Bradenton, Florida, United States

Brooksville, Florida, United States

Hallandale Beach, Florida, United States

Jupiter, Florida, United States

Miami, Florida, United States

Orlando, Florida, United States

Pembroke Pines, Florida, United States

St Petersburg, Florida, United States

Tampa, Florida, United States

Winter Park, Florida, United States

Roswell, Georgia, United States

Chicago, Illinois, United States

Evergreen Park, Illinois, United States

Gurnee, Illinois, United States

Avon, Indiana, United States

Greenfield, Indiana, United States

Lexington, Kentucky, United States

Paducah, Kentucky, United States

Baltimore, Maryland, United States

Columbia, Missouri, United States

Omaha, Nebraska, United States

Las Vegas, Nevada, United States

Margate, New Jersey, United States

Albuquerque, New Mexico, United States

Brooklyn, New York, United States

Calabash, North Carolina, United States

Greensboro, North Carolina, United States

Lenoir, North Carolina, United States

Morehead City, North Carolina, United States

Salisbury, North Carolina, United States

Wilmington, North Carolina, United States

Winston-Salem, North Carolina, United States

Centerville, Ohio, United States

Cincinnati, Ohio, United States

Oklahoma City, Oklahoma, United States

Downingtown, Pennsylvania, United States

Fleetwood, Pennsylvania, United States

Reading, Pennsylvania, United States

Providence, Rhode Island, United States

Anderson, South Carolina, United States

Chattanooga, Tennessee, United States

Kingsport, Tennessee, United States

Nashville, Tennessee, United States

Dallas, Texas, United States

Houston, Texas, United States

Irving, Texas, United States

North Richland Hills, Texas, United States

Pearland, Texas, United States

San Antonio, Texas, United States

Salt Lake City, Utah, United States

Burke, Virginia, United States

Manassas, Virginia, United States

Richmond, Virginia, United States

Virginia Beach, Virginia, United States

Wauwatosa, Wisconsin, United States

Additional Information

EDARBI Package Insert

FDA Safety Alerts and Recalls

Starting date: January 2012
Last updated: April 20, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017